Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
about
Recent advances in the management of renal cell carcinomaRadiation meets immunotherapy - a perfect match in the era of combination therapy?Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceCISH and susceptibility to infectious diseasesA phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.Immunologics and chemotherapeutics for renal cell carcinoma.Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunityToll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model.Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyIn vivo suppression of naive CD4 T cell responses by IL-2- and antigen-stimulated T lymphocytes in the absence of APC competition.Rebuilding immunity in cancer patients.Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.Targeting intracellular signaling: a novel approach to vaccination.Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.Interleukins and cancer immunotherapy.A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.Delivering safer immunotherapies for cancer.IL-10: Expanding the Immune Oncology Horizon.New drug approvals in acute myeloid leukemia: what's the best end point?Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma.
P2860
Q26750609-10617F9D-5209-42A7-A845-CCD0D45A0D3CQ27005913-6ABB7E88-BA7A-4213-8072-65093B573160Q28068959-448D3CAC-2AE5-4BE4-AE2A-E6F2A4689B8BQ28282872-A30C91E0-F688-43C5-A5C4-F49DF8BE9A19Q33393378-434B3E52-F43E-428E-8766-D156D2359EE6Q33689478-E8FBBD5A-9D36-451C-8E1A-D24A8D741EAAQ34278609-7E4C8F9E-B9FE-4E1B-9A6A-F95D1C82C805Q34606479-5F453CB3-1AF0-40EF-9E72-56AC43CA3CE3Q34660154-7BF92AB4-BFDC-4BCB-9415-456ED48E74A3Q35060537-4060E0DD-BC45-449C-9BC0-FEACE2E64A16Q35865283-D1091459-A5CC-46D6-817D-D4FF9B6AE2B5Q35894702-566BCA29-3AEC-458C-A8A2-2354858DA6F2Q36318627-3BE0F790-7C67-45EE-A17C-5BE1BE501B3CQ36920125-FD138B1C-A56E-4718-AF00-181F01998F2AQ36934947-B6CE0AD5-9A97-4DF1-B757-66494216A789Q36943848-1F61DEA0-AC88-4C05-A15D-67C09166570FQ37097532-5FE415F8-7515-4CB9-978D-2EA9C6DDEA1CQ37123459-7517CDE2-ADAA-4DB2-8123-7AA99EABF7DAQ37383688-C72F1470-E7E3-42B7-9E09-61AFA702A0CFQ37773302-EE3BB2FC-3F6E-40C6-A6F7-B22ABD4CDB63Q37809571-E4ACE589-979D-40FF-AE1C-4CA6B285012EQ39064758-1125DB05-3B06-4F79-B899-78CBA60C1523Q39330984-6C888E67-DD25-41DE-802C-D4F00DC57289Q40217856-1CD519FC-1522-4874-975A-5BBF7D9B92A0Q42637732-A899CCD1-9D63-4B48-96DD-C1C5840888A8Q44703429-2FAD89E6-A391-4E16-BF2B-7F54B80BE913Q54318803-99A126F1-28B9-4BAA-9224-B2E85C3D02FD
P2860
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@ast
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@en
type
label
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@ast
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@en
prefLabel
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@ast
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@en
P1476
Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
@en
P2093
David F McDermott
P304
P356
10.1158/1078-0432.CCR-06-1872
P407
P433
P577
2007-01-01T00:00:00Z